SNORD64: A Potential Drug Target for Neurodegenerative Diseases

Target Name: SNORD64

NCBI ID: G347686

SNORD64

Other Name(s): HBII-13 | Small nucleolar RNA, C/D box 64 | small nucleolar RNA, C/D box 64

SNORD64: A Potential Drug Target for Neurodegenerative Diseases

SNORD64 (HBII-13) is a protein that is expressed in various tissues of the body, including the brain, heart, and liver. It is a member of the superfamily of RNA-binding proteins known as Nucleotide-binding proteins (NBPs), which are a group of proteins that interact with specific nucleotides in order to regulate various cellular processes. SNORD64 is of particular interest as a potential drug target or biomarker due to its unique structure and the involvement of various diseases.

The protein encoded by SNORD64 is composed of 216 amino acid residues, with its highest concentration occurring in the N-terminus region. It has a characteristic Rossmann-fold, which is a type of structural motif that is commonly found in proteins that interact with nucleotides. This motif is responsible for the protein's ability to bind specifically to DNA or RNA sequences that contain a specific base.

SNORD64 has been shown to play a role in various cellular processes, including DNA replication, transcription, and translation. In addition, it has been linked to a number of diseases, including neurodegenerative diseases, cancer, and cardiovascular disease. This has led to the conclusion that SNORD64 may be a valuable drug target or biomarker for these diseases.

One of the key challenges in studying SNORD64 is its expression and localization in different tissues. Despite its prevalence, the exact mechanisms by which SNORD64 is expressed and retained in various cell types are not well understood. However, studies have shown that SNORD64 is expressed in a variety of tissues, including the brain, heart, and liver, and that it is highly localized to the endoplasmic reticulum (ER) and nuclear specimen.

In addition to its localization, the structure and function of SNORD64 have also been studied in order to understand its potential as a drug target. Studies have shown that SNORD64 has a number of unique features that make it an attractive candidate for drug targeting, including a high degree of homogeneity, a unique monomeric structure, and a stable catalytic active site.

One of the most promising aspects of SNORD64 is its potential as a drug target for neurodegenerative diseases. neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of debilitating symptoms. These diseases are often treated with drugs that aim to correct the underlying neurological defects, but the ultimate goal is to halt the progression of the disease and improve the quality of life for the patient.

SNORD64 has been shown to play a role in the development and progression of neurodegenerative diseases. For example, studies have shown that SNORD64 is highly expressed in the brains of individuals with Alzheimer's disease, and that its levels are correlated with the severity of the disease. Additionally, SNORD64 has been shown to be involved in the regulation of neurotransmitter release from neurons, which is a key aspect of the development and progression of neurodegenerative diseases.

In addition to its potential as a drug target, SNORD64 has also been shown to be a valuable biomarker for the diagnosis and monitoring of neurodegenerative diseases. The ability to detect and measure the levels of SNORD64 in brain tissue has the potential to provide valuable information about the progression of the disease and the effectiveness of any treatments.

In conclusion, SNORD64 is a protein that has garnered significant interest due to its unique structure and the involvement of various diseases. Its potential as a drug target or biomarker makes it an attractive candidate for further study and potential clinical applications. Further research is needed to fully understand the mechanisms by which SNORD64 interacts with its downstream targets and to explore its potential as a therapeutic approach for

Protein Name: Small Nucleolar RNA, C/D Box 64

The "SNORD64 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD64 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets